News stories about Abaxis (NASDAQ:ABAX) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Abaxis earned a news impact score of 0.17 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 46.1073830639237 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Global Cholesterol Test Kits Market 2018, Alere, Abbott, Beckman Coulter, Inc., Chek Diagnostics, Beckman Coulter (lincolntrailpublishing.com)
- Abaxis Inc (ABAX) Receives Consensus Recommendation of “Hold” from Brokerages (americanbankingnews.com)
- Head to Head Comparison: Amedica (AMDA) and Abaxis (ABAX) (americanbankingnews.com)
- Abaxis Inc Expected to Post Q3 2019 Earnings of $0.33 Per Share (ABAX) (americanbankingnews.com)
- Northcoast Research Equities Analysts Boost Earnings Estimates for Abaxis Inc (ABAX) (americanbankingnews.com)
Shares of Abaxis stock opened at $73.81 on Thursday. The stock has a market cap of $1,658.32, a price-to-earnings ratio of 68.44, a P/E/G ratio of 12.45 and a beta of 1.27. Abaxis has a fifty-two week low of $43.66 and a fifty-two week high of $78.53.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 15th. Investors of record on Thursday, March 1st were issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date was Wednesday, February 28th. Abaxis’s dividend payout ratio is presently 59.26%.
ABAX has been the topic of several research analyst reports. Stifel Nicolaus boosted their price target on shares of Abaxis from $48.00 to $57.00 and gave the company a “hold” rating in a report on Friday, January 26th. BidaskClub cut shares of Abaxis from a “hold” rating to a “sell” rating in a report on Tuesday, December 12th. Zacks Investment Research upgraded shares of Abaxis from a “strong sell” rating to a “hold” rating in a report on Tuesday, December 26th. Northcoast Research upgraded shares of Abaxis from a “neutral” rating to a “buy” rating in a report on Friday, January 5th. Finally, Canaccord Genuity restated a “hold” rating and set a $65.00 price target on shares of Abaxis in a report on Monday, January 29th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the stock. Abaxis presently has a consensus rating of “Hold” and a consensus target price of $62.30.
In related news, insider Kenneth Aron sold 1,412 shares of the company’s stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $69.59, for a total value of $98,261.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael D. Casey sold 5,000 shares of the company’s stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $71.07, for a total transaction of $355,350.00. Following the completion of the sale, the director now owns 27,290 shares of the company’s stock, valued at $1,939,500.30. The disclosure for this sale can be found here. Insiders sold 25,662 shares of company stock valued at $1,804,604 over the last quarter. 4.30% of the stock is currently owned by corporate insiders.
Abaxis, Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force.
Receive News & Ratings for Abaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abaxis and related companies with MarketBeat.com's FREE daily email newsletter.